

STEP THERAPY POLICY

- POLICY:** Ophthalmic Nonsteroidal Anti-Inflammatory Drugs Step Therapy Policy
- Acular® (ketorolac tromethamine 0.5% ophthalmic solution – Allergan, generic)
 - Acular LS® (ketorolac tromethamine 0.4% ophthalmic solution – Allergan, generic)
 - Acuvail® (ketorolac tromethamine 0.45% ophthalmic solution – Allergan)
 - Bromfenac 0.09% ophthalmic solution (generic only)
 - BromSite® (bromfenac 0.075% ophthalmic solution – Sun, generic)
 - Diclofenac 0.1% ophthalmic solution (generic only)
 - Flurbiprofen 0.03% ophthalmic solution (generic only)
 - Nevanac® (nepafenac 0.1% ophthalmic suspension – Novartis)

REVIEW DATE: 11/01/2023; selected revision 03/06/2024

OVERVIEW

In general, the ophthalmic nonsteroidal anti-inflammatory drugs (NSAIDs) are indicated for the management of **ocular pain and inflammation in the postoperative setting**.¹⁻⁷ Note that the specific labeled indications may differ among the products. Ketorolac 0.5% ophthalmic solution is also indicated for the treatment of seasonal allergic conjunctivitis.¹ Flurbiprofen 0.03% ophthalmic solution is not indicated for use in the postoperative setting; flurbiprofen is indicated for the inhibition of intraoperative miosis.⁸ All of the ophthalmic products included in this Step Therapy are preserved with benzalkonium chloride, except Acuvail, diclofenac 0.1% ophthalmic solution, and flurbiprofen 0.03% ophthalmic solution.¹⁻⁸

POLICY STATEMENT

This program has been developed to encourage the use of a Step 1 Product prior to the use of a Step 2 Product. If the Step Therapy rule is not met for a Step 2 Product at the point of service, coverage will be determined by the Step Therapy criteria below. All approvals are provided for 1 year in duration.

Note: Ilevro and Prolensa are not included in this policy.

Automation: A patient with a of one Step 1 Product within the 130-day look-back period is excluded from Step Therapy.

Step 1: generic bromfenac 0.075% ophthalmic solution, generic bromfenac 0.09% ophthalmic solution, generic diclofenac 0.1% ophthalmic solution, generic flurbiprofen 0.03% ophthalmic solution, generic ketorolac 0.4% ophthalmic solution generic ketorolac 0.5% ophthalmic solution

Step 2: Acular, Acular LS, Acuvail, BromSite, Nevanac

CRITERIA

1. If the patient has tried one Step 1 Product, approve a Step 2 Product.
2. No other exceptions are recommended.

REFERENCES

11/01/2023

© 2023. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

Ophthalmic Nonsteroidal Anti-Inflammatory Drugs Step Therapy Policy

Page 2

1. Acular[®] ophthalmic solution [prescribing information]. Irvine, CA: Allergan; May 2012.
2. Acular LS[®] ophthalmic solution [prescribing information]. Irvine, CA: Allergan; June 2016.
3. Acuvail[®] ophthalmic solution [prescribing information]. Irvine, CA: Allergan; February 2019.
4. Nevanac[®] ophthalmic suspension [prescribing information]. East Hanover, NJ: Novartis; November 2020.
5. Bromfenac 0.09% ophthalmic solution [prescribing information]. Bedminister, NJ: Alembic; November 2022.
6. Diclofenac 0.1% ophthalmic solution [prescribing information]. Tampa, FL: Bausch & Lomb; June 2022.
7. BromSite[®] ophthalmic solution [prescribing information]. Cranbury, NJ: Sun; March 2023.
8. Flurbiprofen 0.03% ophthalmic solution [prescribing information]. Tampa, FL: Bausch & Lomb; September 2022.